Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna\u2019s COVID-19 Vaccine in Saudi Arabia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SAUDI ARABIA","productType":"Vaccine","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Ltd Partners with Tabuk Pharmaceuticals to Commercialise Its Speciality Generic Medicines in the Middle East","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SAUDI ARABIA","productType":"Peptide","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tabuk And Cumberland Partner To Bring Innovative Antibiotic With Life-Saving Potential To Middle East","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SAUDI ARABIA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Levolta Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Levolta Pharmaceuticals Partners with Tabuk Pharmaceuticals for Commercialization of Investigational Osteoarthritis Therapy in Middle East and Africa","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SAUDI ARABIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Tabuk Pharmaceuticals

    Menu

    Tabuk Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tabuk Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Saudi Arabia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Levolta Pharmaceuticals Partners with Tabuk Pharmaceuticals for Commercialization of Investigational Osteoarthritis Therapy in Middle East and Africa

              Details:

              The agreement aims for the commercialization of an investigational osteoarthritis (OA) therapy, VOLT01 (zoledronic acid), a patented novel combination drug, in the Middle East and Africa (MEA) region, excluding South Africa.

              Lead Product(s): Zoledronic Acid Derivative

              Therapeutic Area: Musculoskeletal Product Name: VOLT01

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Recipient: Levolta Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tabuk Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Saudi Arabia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tabuk And Cumberland Partner To Bring Innovative Antibiotic With Life-Saving Potential To Middle East

              Details:

              Vibativ® (telavancin) Injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA.

              Lead Product(s): Telavancin Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: Vibativ

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Cumberland Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tabuk Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Saudi Arabia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biocon Ltd Partners with Tabuk Pharmaceuticals to Commercialise Its Speciality Generic Medicines in the Middle East

              Details:

              Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products including Glaricon and be responsible to register, importing, and promoting them in Saudi Arabia and other Middle East countries.

              Lead Product(s): Insulin Glargine

              Therapeutic Area: Endocrinology Product Name: Glaricon

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Biocon

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement December 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tabuk Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Saudi Arabia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi Arabia

              Details:

              Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine, mRNA-1273 in Saudi Arabia. The agreement also gives Tabuk the possibility to discuss opportunities to distribute other Moderna mRNA products if authorized in the future.

              Lead Product(s): mRNA-1273

              Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273

              Highest Development Status: Approved Product Type: Vaccine

              Recipient: Moderna Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY